2022
DOI: 10.1007/s10549-022-06558-8
|View full text |Cite
|
Sign up to set email alerts
|

Safe perioperative tamoxifen use in autologous breast free flap reconstruction: systematic review and meta-analysis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 20 publications
0
1
0
Order By: Relevance
“…Typically, this interruption in Tamoxifen treatment was deemed acceptable without significant risk of cancer progression or recurrence, although conclusive evidence is still lacking [61]. Webster et al have demonstrated that, compared to patients who did not receive Tamoxifen perioperatively, those who received Tamoxifen did not have an increased risk of thrombotic flap complications after an autologous breast free flap reconstruction surgery [62].…”
Section: Tamoxifenmentioning
confidence: 99%
“…Typically, this interruption in Tamoxifen treatment was deemed acceptable without significant risk of cancer progression or recurrence, although conclusive evidence is still lacking [61]. Webster et al have demonstrated that, compared to patients who did not receive Tamoxifen perioperatively, those who received Tamoxifen did not have an increased risk of thrombotic flap complications after an autologous breast free flap reconstruction surgery [62].…”
Section: Tamoxifenmentioning
confidence: 99%
“…The pathogenesis of seroma formation is not completely clear; however, several factors have been reported as probable causes. These factors include age (Lembo et al, 2021), hypertension (Hwang et al, 2021), elevated body mass index (Caputo et al, 2021), number of malignant nodules (da Costa Vieira et al, 2021), and the use of electrosurgery (Sforza et al, 2017; Watkins et al, 2008; Webster et al, 2022).…”
mentioning
confidence: 99%